Xin Lang Cai Jing·2025-09-15 10:40Core Viewpoint - Baiyunshan's subsidiary, Baiyunshan Pharmaceutical Factory, has received feedback from the National Medical Products Administration (NMPA) regarding its selective RET small molecule inhibitor, BYS10 tablets, which are intended for the treatment of advanced solid tumors such as non-small cell lung cancer and medullary thyroid carcinoma [1] Summary by Categories Product Development - BYS10 tablets have undergone research and development with an investment of RMB 146 million [1] - The NMPA has agreed to allow BYS10 tablets to apply for market approval through a Phase II single-arm clinical trial [1] Market Context - Currently, only two RET inhibitors, Pralsetinib (BLU-667) and Selpercatinib (LOXO-292), have been approved for market release globally [1]